GlassScriptPhysician profile
David Mesibov
NPI 1912001520
$5,396.73
in general payments reported to CMS, 2019-2025
33 companies · $555 in 2025
The $555 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $827 · 2020: $597 · 2021: $947 · 2022: $999 · 2023: $819 · 2024: $653 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,027.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $903.33 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $675.31 | 2019-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $639.78 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $586.28 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $498.29 | 2019-2023 | |
| Abbvie INC. | $345.93 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $262.75 | 2019-2025 | Capvaxive |
| Novo Nordisk INC | $156.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.07 | 2021-2025 | Xifaxan, Trulance |
| Pfizer INC. | $149.29 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $141.85 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $110.35 | 2021-2023 | |
| Amarin Pharma, INC. | $93.22 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $80.55 | 2019-2022 | |
| Exact Sciences Corporation | $57.41 | 2023-2024 | Cologuard Collection Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $54.09 | 2021-2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.67 | 2022-2023 | |
| Recordati_rare_diseases_inc. | $47.68 | 2025 | Isturisa |
| Astellas Pharma US INC | $47.49 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $44.99 | 2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $38.90 | 2024-2025 | Gvoke Hypopen |
| Madrigal Pharmaceuticals | $35.11 | 2024 | Resmetirom |
| Amgen INC. | $31.28 | 2023-2025 | Repatha, Evenity |
| Becton, Dickinson and Company | $28.56 | 2021 | |
| Biodelivery Sciences International, INC. | $25.74 | 2021 | |
| Sanofi Pasteur INC. | $22.26 | 2019 | |
| Insulet Corporation | $21.95 | 2024 | Omnipod |
| Ascendis Pharma Endocrinology INC | $17.58 | 2025 | Yorvipath |
| Bioventus LLC | $16.12 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.74 | 2022 | |
| Allergan, INC. | $14.56 | 2019 | |
| Radius Health, INC. | $14.27 | 2020 | |
| Eisai INC. | $13.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mesibov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.